Low-Dose Oral Minoxidil (LDOM) for Androgenetic Alopecia
Verdict: Published with Warning
Across 5 PubMed studies, the evidence for Low-Dose Oral Minoxidil (LDOM) in Androgenetic Alopecia grades Tier A — moderate evidence. Effective, but with safety or population caveats.
A 🔵 A Moderate Evidence Published with Warning
Why this grade7-layer evidence engine
⚖️
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditableRaw score 0.73
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
A · Published with Warning
Confidence
85%
Highly consistent evidence
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)
▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.728
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PubMed studies (5)L2 · primary research & systematic reviews
Efficacy and safety of oral minoxidil versus topical solution in androgenetic alopecia: a meta-analysis of randomized clinical trials
Finding: Pooled across 4 RCTs (n=279), oral and topical minoxidil produced statistically indistinguishable hair-density gains (SMD 0.02, 95% CI -0.25 to 0.29, p=0.88), but oral caused significantly more hypertrichosis (RR 2.01, 95% CI 1.18-3.41, p=0.01).
View on PubMed Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial
Finding: Oral minoxidil 5 mg/day did NOT demonstrate superiority over topical 5% at 24 weeks (frontal between-group difference 3.1 hairs/cm2, 95% CI -18.2 to 21.5, p=0.27; vertex 23.4 hairs/cm2, 95% CI -0.3 to 43.0, p=0.09), while hypertrichosis was more frequent with oral (49% vs 25%, p=0.02).
View on PubMed There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: Findings from a Systematic Review with Meta-Regression Analyses
Finding: Across 6 studies (dose 0.25-5 mg/day), each additional 1 mg/day was associated with a +47.1 hairs/cm2 gain in total hair density (p=0.007) and +9.1 hairs/cm2 in terminal hair density (p=0.001), supporting a dose-dependent efficacy.
View on PubMed Efficacy and safety of oral minoxidil in the treatment of alopecia: a single-arm rate meta-analysis and systematic review
Finding: Pooling 27 single-arm studies (n=2,933), oral minoxidil yielded a significant-improvement rate of 35% (95% CI 22-49%) and overall improvement of 47% (95% CI 38-55%), with a 27% adverse-event rate (95% CI 18-36%); benefit was greater at doses >1 mg, but the uncontrolled single-arm design provides no placebo comparison.
View on PubMed Analysing efficacy of low-dose oral minoxidil, topical minoxidil, and PRP with topical minoxidil in androgenetic alopecia: a randomized controlled observer-blinded trial
Finding: At 32 weeks, oral minoxidil (G1, +47.5%) and topical minoxidil (G2, +48%) gave near-identical terminal-hair-density gains, with only the PRP+topical arm (G3, +57%) significantly superior (G3 vs G1 p=0.03; G3 vs G2 p=0.02), i.e. oral was comparable to but not better than topical.
View on PubMed Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …
L4a US FDA
Cautious
BOXED WARNING: 'Minoxidil tablets contain the powerful antihypertensive agent, minoxidil, which may produce serious adverse effects. It can cause pericardial effusion, occasionally progressing to tamponade, and angina pectoris may be exacerbated. Minoxidil must be administered under close supervision, usually concomitantly with therapeutic doses of a beta-adrenergic blocking agent to prevent ta… source↗
L4b EU EFSA
Cautious
Minoxidil and its salts must not be used in cosmetic products because of their antihypertensive activity. Minoxidil absorption after scalp application could lead to systemic effects. [Minoxidil is] a peripheral vasodilatator acting on vascular smooth muscle cells, used as a drug in the management of severe hypertension. [The substance is] cardiotoxic in long term oral studies. source↗
L4c UK NHS
Cautious
Minoxidil foam (Regain) is the only licensed treatment for female and male pattern hair loss. You will start on a 0.625mg dose on alternate days; any further changes to the dose will be discussed in your follow up consultations. While you are receiving minoxidil treatment you should have your pulse and blood pressure monitored regularly by your GP. This treatment is not advised for individuals … source↗
L4d TW TFDA / 衛福部
Cautious
洛寧錠10毫克 LONITEN 10MG 衛署藥輸字 第 007538 號 須由醫師處方使用；目前口服 minoxidil 的適應症還是只有用在高血壓，用在治療落髮還是屬於適應症外用藥。 source↗
L4e WHO
Neutral
Minoxidil belongs to the drug class of direct-acting peripheral vasodilators. It exerts its antihypertensive effect by opening adenosine triphosphate (ATP)-sensitive potassium channels, thereby reducing peripheral resistance and lowering blood pressure. The FDA approved minoxidil in tablet form in 1979 under the brand name Loniten specifically for treatment of high blood pressure. Low-dose oral… source↗
L5a NIH Office of Dietary Supplements
Cautious
LONITEN (minoxidil tablets) is indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. Elongation, thickening, and enhanced pigmentation of fine body hair are seen in about 80% of patients taking LONITEN Tablets. This develops within 3 to 6… source↗
L5b Mayo Clinic
Neutral
This medicine causes a temporary increase in hair growth in most people. The hair grows longer and darker in both men and women. This may first be noticed on the face several weeks after you start taking minoxidil. Later, new hair growth may be noticed on the back, arms, legs, and scalp. After treatment with minoxidil has ended, the hair will stop growing, although it may take several months fo… source↗
L5c Cleveland Clinic
Supportive
Off-label, low-dose oral minoxidil, which is inexpensive and proving to be safe and quite effective on its own or in combination with topical treatments... We start with 2.5 mg pills and have our patients split them to 0.625 or, more commonly, 1.25 milligrams a day. It has really been the best drug we ever had for hair growth. In a review of 1,404 Cleveland Clinic patients on the regimen, nearl… source↗
L5d Harvard Health
Supportive
Recent studies suggest that taking minoxidil as a pill, which has been used for decades to treat high blood pressure, is safe and effective for treating hair loss. source↗
L5e Specialty Society (condition-mapped)
Supportive
Low dose oral minoxidil is another treatment option for hereditary hair loss. While this medication has been available for some time, it is being used more commonly and is an option for many of my patients, who have said that it is convenient and easy to use. source↗